Phase 2 N=303 UARK 2003-33, Total Therapy III
Multiple Myeloma
Primary: Percentage of Participants With Progression-Free Survival (PFS) at 3 Years From Initiation of Study Treatment — 77 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Effects of Low Dose Naltrexone in Fibromyalgia
Fibromyalgia · Persian Gulf Syndrome
Primary: Percent Change in Pain Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment. — 28.8; 18.0 percentage change from baseline to…
Phase 2 N=54 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Overall Response Rate — 9 percentage of participants
Phase 4 N=52 Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
Chronic Migraine
Primary: Change From Baseline in the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire Total Score — 50.5; 47.2; -25.2; -20.5 Scores on a Scale
N/A N=99 Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy
Cholecystitis
Primary: Complications Related to ICG — 0; 0 % of Participants with Complications
Phase 2 N=47 Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer · Non-Small Cell Lung Cancer
Primary: Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride — 70 mg/day
Phase 1 N=18 Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
Multiple Sclerosis
Primary: Maximum Plasma Concentration (Cmax) of Cladribine — 20.7; 20.3 nanogram/milliliter
Phase 3 N=113 Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
Hepatitis C
Primary: Percentage of HCV Genotype-1 Infected Post-liver Transplanted Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) — 95.1 Percentage of…
Phase 3 N=2,259 Vitamin D/Calcium Polyp Prevention Study
Colorectal Cancer · Polyps · Adenomas
Primary: Colorectal Adenomas — 48.2; 44.9; 47.0; 45.7 percentage of subjects
Phase 3 N=534 Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 — -0.88; -1.20; -1.47 % HbA1c — p=<0.0001
N/A N=18 Evidence Based Amputee Rehabilitation (EBAR) Program
Amputation Stumps · Diabetes Mellitus
Primary: Amputee Mobility Predictor — 36.4; 35.3; 41.7; 35.6 Points
N/A N=80 Purge Vs no Purge in Living Donor Liver Transplantation Recipients
Ischemia Reperfusion Injury
Primary: Lowest 5 Minutes Post-reperfusion Mean Arterial Blood Pressure — 66.03; 57.75 mmHg
Phase 2 N=168 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months
Phase 2 N=12 Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.
Alzheimer's Disease
Primary: Cognitive Performance — 15.92; 16.67; 8.58; 8.41 mean total correct responses — p=<0.05
Phase 2 N=126 A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.
Human Influenza
Primary: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm^2, Against Each of Three Vaccine Strains After Receiving One Dose of TIV. — 62; 52; 51; 40…